



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated:21-10-2008

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE WEEKENDING 04-10-2008 TO BE PUBLISHED 22-10-2008 IN THE GAZETTE OF PAKISTAN PART-V.

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 21-10-2008

To,

Mr. Manzoor Ahmed
Section Officer
Cabinet Secretariat
Cabinet Division
Government of Pakistan
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 04-10-2008 TO BE PUBLISHED 22-10-2008 IN THE
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23rd April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1156/2008	<u>29-9-2008</u> Lurgi Zimmer GmbH Germany (Priority 23-10-07 Germany)	“Method and device for producing vacuum the production of polyesters and copolyesters”
1157/2008	F.L. Smidth A/S, Denmark (Priority 11-12-07 Denmark)	“A roller mill”
1158/2008	CHI Fuchen China (Priority 25-2-08 China)	“Multifunctional retrievable soccer”
1159/2008	Amcol International Corporation USA (Priority 04-10-07 USA)	“Composition and method for the solidification of toxic or hazardous drilling and agricultural waste”
1160/2008	<u>30-9-2008</u> Boehringer Ingelheim Pharma GmbH and Co. KG., Germany (Priority 20-3-02 Germany) Divisional	“Crystalline mikronisate”
1161/2008	Sanofi-Aventis Deutschland GmbH Germany (Priority 05-10-07 Europe)	“Use of sulfonyl-substituted 2-sulfonylamino benzoic acid N-phenylamides in the treatment of pain”
1162/2008	Sanofi-Aventis Germany (Priority 03-10-07 France)	“Quinazolinedione derivatives their preparation and their therapeutic applications”

	<u>04-10-2008</u>	
1163/2008	Acucela, Inc. USA (Priority 05-10-07 USA)	“Alkoxy compounds for disease treatment”
1164/2008	Glaxo Group Limited, United Kingdom (Priority 05-10-07 USA)	Immunoglobulins”
1165/2008	Joshua Haibed USA (Priority 02-10-07 USA)	“Looking ring actuator for a pressure retaining closure”
1166/2008	MGI GP, Inc. USA (Priority 03-10-07 USA)	“Parp inhibitor compositions and method of use”
1167/2008	Mitsubishi Tanabe Pharma Corporation Japan (Priority 02-2-06 Japan) Divisional	“A pharmaceutically acceptable salt of a nitrogen-containing meterobicyclic compound”
1168/2008	Otsuka Pharmaceutical Co, Ltd. Japan (Priority 27-12-05 Japan) Divisional	“A salt of a water-soluble benzoazepine compound and its pharmaceutical composition”



APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


15/1999 Glaxo Group
 Limited.
 Great Britain

“A compound N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-methanesulphonyl]ethyl]amino)methyl]-2-furyl]-4-quinazolinamine and pharmaceutical composition thereof”

(CO7D, 405/04)

139810

Substituted heteroaromatic compound of formula (I)



wherein X is N or CH;

Y is CR¹ and V is N;
or Y is N and V is CR¹;
or Y is CR¹ and V is CR²;
or Y is CR² and V is CR¹

R^1 represents a group $CH_3SO_2CH_2CH_2NHCH_2-Ar$, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C_{1-4} alkyl or C_{1-4} alkoxy groups;

R^2 is selected from the group comprising hydrogen, halo, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylamino and di[C_{1-4} alkyl]amino;


U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1H-benzimidazolyl or 1H-benzotriazolyl group, substituted by an R^3 group and optionally substituted by at least one independently selected R^4 group;

R^3 is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl,

benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl;

or R^3 represents trihalomethylbenzyl or trihalomethylbenzyloxy;

or R^3 represents a group of formula



wherein each R^5 is independently selected from halogen, C_{1-4} alkyl and C_{1-4} alkoxy; and n is 0 to 3;

each R^4 is independently hydroxy, halogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, amino, C_{1-4} alkylamino, di[C_{1-4} alkyl]amino,

C₁₋₄ alkylthio, C₁₋₄ alkyisulphinyl, C₁₋₄ alkylsulphonyl, C₁₋₄ alkylcarbonyl, carboxy, carbamoyl, C₁₋₄ alkoxy carbonyl, C₁₋₄ alkanoyl, gmino, N-(C₁₋₄ alkyl) carbamoyl, N,N-di(C₁₋₄ alkyl)carbamoyl, cyano. Nitro and trifluoromethyl; and salt and solvates thereof are disclosed, pharmaceutical composition containing them and their use in medicine.


845/2006 Glaxo Group Limited Great Britain

“A pharmaceutically acceptable salt of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-([2-(methanesulphonyl)ethyl]amino)methyl]-2-furyl]-4-quinazolinamine and pharmaceutical composition thereof”

(C07D, 405/04)

139811

A pharmaceutical salt of substituted heteroaromatic compound of formula (I)



wherein X is N or CH;

Y is CR¹ and V is N;
 or Y is N and V is CR¹;
 or Y is CR¹ and V is CR²;
 or Y is CR² and V is CR¹

R¹ represents a group CH₃SO₂CH₂NHCH₂-Ar-, wherein Ar is selected from phenyl, furan, thiophene, pyrrole and thiazole, each of which may optionally be substituted by one or two halo, C₁₋₄ alkyl or C₁₋₄ alkoxy groups;

R^2 is selected from the group comprising hydrogen, halo, hydroxy, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylamino and di[C_{1-4} alkyl]amino;


U represents a phenyl, pyridyl, 3H-imidazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, 1H-indazolyl, 2,3-dihydro-1H-indazolyl, 1H-benzimidazolyl, 2,3-dihydro-1 H-benzimidazolyl or 1 H-benzotriazolyl group, substituted by an R^3 group and optionally substituted by at least one independently selected R^4 group;

R^3 is selected from a group comprising benzyl, halo-, dihalo- and trihalobenzyl,

benzoyl, pyridylmethyl, pyridylmethoxy, phenoxy, benzyloxy, halo-, dihalo- and trihalobenzyloxy and benzenesulphonyl;

or R^3 represents trihalomethylbenzyl or trihalomethylbenzyloxy;

or R^3 represents a group of formula



wherein each R^5 is independently selected from halogen, C_{1-4} alkyl and C_{1-4} alkoxy; and n is 0 to 3;

each R^4 is independently hydroxy, halogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, amino, C_{1-4} alkylamino, di[C_{1-4} alkyl]amino, C_{1-4} alkylthio, C_{1-4} alkylsulphinyl, C_{1-4} alkylsulphonyl, C_{1-4} alkylcarbonyl, carboxy, carbamoyl, C_{1-4} alkoxy carbonyl, C_{1-4} alkanoyl, amino, N-(C_{1-4} alkyl) carbamoyl, N,N-di(C_{1-4} alkyl)carbamoyl, cyano. Nitro and trifluoromethyl; and salt and solvates thereof are disclosed,

pharmaceutical composition containing them and their use in medicine.

④④④④④④

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139452	Warner-Lambert Company., USA	452/1996
139453	Pfizer Inc., USA	760/1996
139454	Dimminaco AG., Switzerland	79/1998
139455	Pfizer Products Inc., USA	186/1999
139456	F. Hoffmann-La Roche AG., Switzerland	186/1999
139457	Bayer Aktiengesellschaft., Germany.	771/1999
139458	Syngenta Participations AG., Switzerland	981/1999
139459	Pfizer Inc., USA	1022/1999
139460	Almirall Prodesfarma, S.A., Spain	489/2000
139461	Bayer Corporation., USA.	890/2000
139462	Warner-Lambert Company., USA	74/2001
139463	F. Hoffmann-La Roche AG. Switzerland	565/2001
139464	Institute of Molecular Agrobiolgy, Singaopore	599/2001
139465	Syngenta Limited., United Kingdom.	186/2002
139466	Warner-Lambert Company.,	445/2002

139467	USA Pfizer Inc., USA	27/2005
139468	Zimmer AG., Germany	313/2005
139469	Recordati Ireland Limited., Ireland.	946/2005

(MRS. YASMEEN ABBASI)
CONTROLLER OF PATENTS
Tel: 9215488